Evidence map›Paper›PMID 30458782›Full record

ArticleBMC systems biology2018

Pipeline design to identify key features and classify the chemotherapy response on lung cancer patients using large-scale genetic data.

María Gabriela Valdés, Iván Galván-Femenía, Vicent Ribas Ripoll, Xavier Duran, Jun Yokota, Ricard Gavaldà, Xavier Rafael-Palou, Rafael de Cid

Open access · diamondAbstract readValidation Study
In one paragraph

Article in BMC systems biology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.4field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. Trial
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

María Gabriela ValdésEurecat. Technology Centre of Catalonia, Av. Diagonal 177, 9th floor, Barcelona, 08018, Spain. mgvaldesgraterol@gmail.com.
Iván Galván-FemeníaPMPPC-IGTP. Programa de Medicina Predictiva i Personalitzada del Càncer - Institut Germans Trias i Pujol (IGTP). Genomes for Life - GCAT lab Group, Badalona, Spain.
Vicent Ribas RipollEurecat. Technology Centre of Catalonia, Av. Diagonal 177, 9th floor, Barcelona, 08018, Spain. vicent.ribas@eurecat.org.
Xavier DuranPMPPC-IGTP. Programa de Medicina Predictiva i Personalitzada del Càncer - Institut Germans Trias i Pujol (IGTP). Genomes for Life - GCAT lab Group, Badalona, Spain.
Jun YokotaPMPPC-IGTP. Programa de Medicina Predictiva i Personalitzada del Càncer - Institut Germans Trias i Pujol (IGTP). CancerGenome Biology, Badalona, Spain.
Ricard GavaldàUniversitat Politècnica de Catalunya, Barcelona, Spain.
Xavier Rafael-PalouEurecat. Technology Centre of Catalonia, Av. Diagonal 177, 9th floor, Barcelona, 08018, Spain.
Rafael de CidPMPPC-IGTP. Programa de Medicina Predictiva i Personalitzada del Càncer - Institut Germans Trias i Pujol (IGTP). Genomes for Life - GCAT lab Group, Badalona, Spain. rdecid@igtp.cat.
Institute of Predictive and Personalized Medicine of Cancer · ESUniversitat Politècnica de Catalunya · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundDuring the last decade, the interest to apply machine learning algorithms to genomic data has increased in many bioinformatics applications. Analyzing this type of data entails difficulties for managing high-dimensional data, class imbalance for knowledge extraction, identifying important features and classifying individuals. In this study, we propose a general framework to tackle these challenges with different machine learning algorithms and techniques. We apply the configuration of this framework on lung cancer patients, identifying genetic signatures for classifying response to drug treatment response. We intersect these relevant SNPs with the GWAS Catalog of the National Human Genome Research Institute and explore the Regulomedb, GTEx databases for functional analysis purposes.

resultsThe machine learning based solution proposed in this study is a scalable and flexible alternative to the classical uni-variate regression approach to analyze large-scale data. From 36 experiments executed using the machine learning framework design, we obtain good classification performance from the top 5 models with the highest cross-validation score and the smallest standard deviation. One thousand two hundred twenty four SNPs corresponding to the key features from the top 20 models (cross validation F1 mean >= 0.65) were compared with the GWAS Catalog finding no intersection with genome-wide significant reported hits. From these, new genetic signatures in MAE, CEP104, PRKCZ and ADRB2 show relevant biological regulatory functionality related to lung physiology.

conclusionsWe have defined a machine learning framework using data with an unbalanced large data-set of SNP-arrays and imputed genotyping data from a pharmacogenomics study in lung cancer patients subjected to first-line platinum-based treatment. This approach found genome signals with no genome-wide significance in the uni-variate regression approach (GWAS Catalog) that are valuable for classifying patients, only few of them with related biological function. The effect results of these variants can be explained by the recently proposed omnigenic model hypothesis, which states that complex traits can be influenced mostly by genes outside not only by the "core genes", mainly found by the genome-wide significant SNPs, but also by the rest of genes outside of the "core pathways" with apparent unrelated biological functionality.

Indexed as

AlgorithmsAntineoplastic AgentsComputational BiologyDrug Resistance, NeoplasmGenome-Wide Association StudyGenomicsGenotypeHumansLung NeoplasmsMachine LearningPolymorphism, Single NucleotideAntineoplastic AgentsClassificationFeature selectionGWASLung cancerMachine learning

Identifiers

PMID30458782
PMCPMC6245589
OpenAlexW2901747086

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.